A study of palbociclib and fulvestrant for advanced breast cancer that has continued to grow despite hormone treatment (PYTHIA)

This study is looking at adding palbociclib to a hormone treatment called fulvestrant for advanced breast cancer. It is for post menopausal women whose:

• breast cancer has spread to another part of the body (secondary breast cancer) or has come back after treatment in the same place (locally recurred)

• breast cancer cells are oestrogen receptor positive (ER positive)

• breast cancer cells have low or no amounts of a protein called HER2 (HER2 negative cancer)